LLY
EquityEli Lilly and Company
Health Care · Drug Manufacturers - General
$999.31
+999.31 (+0.00%)
Open
N/A
Day Range
$996.17 - $1,015.66
52W Range
$623.78 - $1,133.95
Volume
329K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Eli Lilly (LLY) Valuation Check As Momentum Cools After Strong Multi Year Run
Barclays names 2 drug stocks investors should own in 2026
The Best Healthcare Stock to Invest $1,000 in Right Now
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $3.64 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $233.86 | N/A | 2.84% | +0.00% |
| CRSP | CRISPR Therapeutics AG | $58.06 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $22.50 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $7,280.00 | N/A | 6.04% | +0.00% |
| A | Agilent Technologies, Inc. | $119.04 | N/A | 0.84% | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.48 | N/A | - | +0.00% |
| ABT | Abbott Laboratories | $114.12 | N/A | 2.10% | +0.00% |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
www.lilly.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Safe
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+15.4%
3Y CAGR
+15.2%
5Y CAGR
N/A
10Y CAGR
N/A
5-Year Dividend Projection
| Year | Conservative | Base | Optimistic |
|---|
Based on historical CAGR. Not a guarantee of future dividends.
View Full Projection →Loading financial data...
Revenue & Earnings
No financial statement data available for LLY.